anti human cdk6  (Cell Signaling Technology Inc)

Journal: Molecular and cellular endocrinology

Article Title: DUAL INHIBITION OF ERK1/2 AND AKT PATHWAYS IS REQUIRED TO SUPPRESS THE GROWTH AND SURVIVAL OF ENDOMETRIOTIC CELLS AND LESIONS

doi: 10.1016/j.mce.2018.12.011

Figure Lengend Snippet: Details of the antibody used.

Article Snippet: Anti-human mouse monoclonal CDK6 , Cell Signaling , 3136 , 1:1000.

Techniques: Concentration Assay

Journal: OncoTargets and therapy

Article Title: Long Non-Coding RNA CDKN2B-AS1 Facilitates Laryngeal Squamous Cell Cancer Through Regulating miR-497/CDK6 Pathway

doi: 10.2147/OTT.S221620

Figure Lengend Snippet: CDKN2B-AS1 promotes LSCC progression via regulating miR-497/CDK6 axis. ( A ) The expression of miR-497 was examined in TU212 cells transfected with si-NC, si-CDKN2B-AS1, si-CDKN2B-AS1+miR-497 inhibitor (anti-miR-497) or si-CDKN2B-AS1+CDK6 overexpression plasmid (CDK6). MiR-497 expression was normalized to U6. ( B, C ) The expression of CDK6 on mRNA and protein levels were determined in TU212 cells transfected with si-NC, si-CDKN2B-AS1, si-CDKN2B-AS1+ anti-miR-497, or si-CDKN2B-AS1+CDK6. GAPDH was used as control. ( D ) The mRNA expression of CDK6 was examined by qRT-PCR in LSCC tissues and adjacent normal tissues (ANT). GAPDH was used as control. ( E ) Correlation between CDKN2B-AS1 and CDK6 expression in LSCC tissues was analyzed by Pearson’s correlation analysis. ( F – I ). Cell proliferation, apoptosis, migration and invasion were detected in TU212 cells transfected with si-NC, si-CDKN2B-AS1, si-CDKN2B-AS1+ anti-miR-497 or si-CDKN2B-AS1+CDK6. * P < 0.05; ** P < 0.01.

Article Snippet: The membranes were probed with primary antibodies: mouse monoclonal anti-human CDK6 (1:1000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and mouse monoclonal anti-human GAPDH (1:5000; Santa Cruz Biotechnology, Inc.).

Techniques: Expressing, Transfection, Over Expression, Plasmid Preparation, Control, Quantitative RT-PCR, Migration

Journal: International journal of oncology

Article Title: Metastatic cancer cells compensate for low energy supplies in hostile microenvironments with bioenergetic adaptation and metabolic reprogramming.

doi: 10.3892/ijo.2018.4582

Figure Lengend Snippet: Figure 3. Expression of cell cycle regulation proteins in SW480 and SW620 cells with different metabolic types. (A and B) Representative western blotting images of CDK6, Cyclin D3, Cyclin D1, pCDC2 and CDK4 protein expression in (A) SW480 and (B) SW620 cells cultured in different media; β-actin was used as a loading control. (C-E) Protein expression levels from (A) and (B) were quantified using Image Lab analysis software, and relative expression levels of (C) Cyclin D3, (D) pCDC2 and (E) CDK4 were calculated as a ratio of the same protein in OXPHOS. Data are presented as the mean ± standard deviation; n=3; **P<0.01. CDC, cell division control protein; CDK, cyclin‑dependent kinase; NOR, normal; GLY, glycolysis; OXPH, oxidative phosphorylation.

Article Snippet: Rabbit anti-human p21 (cat. no. 2947), p27 (cat. no. 3686), CDK2 (cat. no. 2546), CDK4 (cat. no. 12790), Cyclin D1 (cat. no. 2978), phosphorylated (p)-cell-division control protein 2 (CDC2; also known as CDK1; cat. no. 4539), β-actin (cat. no. 4970), mouse anti-human CDK6 (cat. no. 3136), Cyclin D3 (cat. no. 2936) and β-actin (cat. no. 3700) antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA).

Techniques: Expressing, Western Blot, Cell Culture, Control, Software, Standard Deviation, Phospho-proteomics

Journal: International journal of oncology

Article Title: Metastatic cancer cells compensate for low energy supplies in hostile microenvironments with bioenergetic adaptation and metabolic reprogramming.

doi: 10.3892/ijo.2018.4582

Figure Lengend Snippet: Figure 4. Expression of cell cycle checkpoint and regulation proteins in SW480 and SW620 cells treated with Oligo A over time. (A) Western blot analysis of CDK2, CDK4, CDK6, p21 and p27 protein expression levels in SW480 and SW620 treated with Oligo A (1 µM) for 0-48 h; β-actin was used as a loading control. (B-E) Protein expression levels from (A) were quantified using Image Lab analysis software, and the relative expression levels of (B) CDK2, (C) CDK4, (D) p21 and (E) p27 were calculated. Data are presented as the mean ± standard deviation; n=3; **P<0.01 and ***P<0.001 vs. SW480. CDK, cyclin‑dependent kinase; Oligo A, Oligomycin A.

Article Snippet: Rabbit anti-human p21 (cat. no. 2947), p27 (cat. no. 3686), CDK2 (cat. no. 2546), CDK4 (cat. no. 12790), Cyclin D1 (cat. no. 2978), phosphorylated (p)-cell-division control protein 2 (CDC2; also known as CDK1; cat. no. 4539), β-actin (cat. no. 4970), mouse anti-human CDK6 (cat. no. 3136), Cyclin D3 (cat. no. 2936) and β-actin (cat. no. 3700) antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA).

Techniques: Expressing, Western Blot, Control, Software, Standard Deviation

Journal: Cell Cycle

Article Title: Altered expression of G1/S phase cell cycle regulators in placental mesenchymal stromal cells derived from preeclamptic pregnancies with fetal-placental compromise

doi: 10.1080/15384101.2016.1261766

Figure Lengend Snippet: CDK4 and CDK6 gene and protein expression levels in normal vs preeclamptic PDMSCs. (A) mRNA (left panel) and protein (right panel) expression of CDK4 in normal (N, n = 20) and PE-PDMSCs (PE, n = 24) (B) (b) mRNA (left panel) and protein (right panel) expression of CDK6 in normal (N, n = 20) and PE-PDMSCs (PE, n = 24). Statistical significance (*) has been considered as p < 0.05.

Article Snippet: Primary antibodies were: rabbit polyclonal anti-human JunB (1:2000 dilution, Merk-Millipore, Cat. No. 07–1333), mouse monoclonal anti-human Cyclin D1 (1:1500 dilution, Cell Signaling, Cat. No. 2978), rabbit monoclonal anti-human p16 INK4A (1:250 dilution, Cell Signaling, Cat.No 4824), mouse monoclonal anti-human p18 INK4C (1:250 dilution, Cell Signaling, Cat.No 2896), mouse monoclonal anti-human CDK4 (1:500 dilution, Cell Signaling, Cat.No 12790), mouse monoclonal anti-human CDK6 (1:500 dilution, Cell Signaling, Cat. No. 3136), mouse monoclonal anti-human PARP1 (1:500 diluition, Abcam, Cat. No. ab110915) and mouse monoclonal anti-human β-actin (1:1000, Sigma-Aldrich, Cat.No.

Techniques: Expressing

Journal: Cell Cycle

Article Title: Altered expression of G1/S phase cell cycle regulators in placental mesenchymal stromal cells derived from preeclamptic pregnancies with fetal-placental compromise

doi: 10.1080/15384101.2016.1261766

Figure Lengend Snippet: CDK4and CDK6 gene and protein expression levels in physiological placental villous explants treated with culture media conditioned by normal or PE-PDMSC. (A) CDK4 mRNA (left panels) and protein (right panels) expression levels in physiological villous explants treated with unconditioned media (CTRL, n = 16 explants) or media conditioned by normal (N CM, n = 16 explants) and preeclamptic (PE CM, n = 16 explants) PDMSCs as assessed by Real Time PCR and Western Blot analysis. B) CDK6 mRNA (left panels) and protein (right panels) expression levels in physiological villous explants treated with unconditioned media (CTRL, n = 16 explants) or media conditioned by normal (N CM, n = 16 explants) and preeclamptic (PE CM, n = 16 explants) PDMSCs as assessed by Real Time PCR and Western Blot analysis. Statistical significance (*) has been considered as p < 0.05.

Article Snippet: Primary antibodies were: rabbit polyclonal anti-human JunB (1:2000 dilution, Merk-Millipore, Cat. No. 07–1333), mouse monoclonal anti-human Cyclin D1 (1:1500 dilution, Cell Signaling, Cat. No. 2978), rabbit monoclonal anti-human p16 INK4A (1:250 dilution, Cell Signaling, Cat.No 4824), mouse monoclonal anti-human p18 INK4C (1:250 dilution, Cell Signaling, Cat.No 2896), mouse monoclonal anti-human CDK4 (1:500 dilution, Cell Signaling, Cat.No 12790), mouse monoclonal anti-human CDK6 (1:500 dilution, Cell Signaling, Cat. No. 3136), mouse monoclonal anti-human PARP1 (1:500 diluition, Abcam, Cat. No. ab110915) and mouse monoclonal anti-human β-actin (1:1000, Sigma-Aldrich, Cat.No.

Techniques: Expressing, Real-time Polymerase Chain Reaction, Western Blot